EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid

Dah Cherng Yeh, Dar Ren Chen, Tsu Yi Chao, Shin Cheh Chen, Hwei Chung Wang, Kun Ming Rau, Yin Hsun Feng, Yuan Ching Chang, Kuan Der Lee, Fu Ou-Yang, Wen Hung Kuo, King Jen Chang, Yung Chang Lin, Ling Ming Tseng, Ming Feng Hou

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: We assessed the effect of zoledronic acid on quality of life (QOL) and pain outcome in breast cancer patients with bone metastases using the European Organization for Research and Treatment of Cancer bone metastases module (EORTC QLQ-BM22). Patients and Methods: Three hundred sixty-six breast cancer patients receiving zoledronic acid for bone metastases from 13 Centers were prospectively enrolled. QOL was evaluated using the EORTC QLQ-BM22 and pain outcome were measured monthly with a Visual Analog Scale (VAS) score for 24 months. Results: No significant change of functional scale (functional interference and psychosocial aspects) of the EORTC QLQ-BM22 was reported. Significant reduction of the symptom scale was noted after treatment compared with the baseline. The painful site subscale was significantly reduced during the first 12 months, with the exception the 6- month follow-up of point. Pain characteristics subscale was also significantly lower from the 2-month time point onwards. VAS scores indicated a significant reduction in pain over the course of the study to the 22-month time point follow-up compared to the baseline. Conclusion: Zoledronic acid treatment improved QOL of breast cancer patients with bone metastases by relieving bone pain.

Original languageEnglish
Pages (from-to)1001-1004
Number of pages4
JournalIn Vivo
Volume28
Issue number5
Publication statusPublished - Sep 1 2014

Fingerprint

zoledronic acid
Bone
Quality of Life
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Pain
Visual Analog Scale
Bone Neoplasms
Therapeutics
Organizations

Keywords

  • Bone metastases
  • Breast cancer
  • Pain
  • Quality of life
  • Zoledronic acid

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology
  • Medicine(all)

Cite this

Yeh, D. C., Chen, D. R., Chao, T. Y., Chen, S. C., Wang, H. C., Rau, K. M., ... Hou, M. F. (2014). EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid. In Vivo, 28(5), 1001-1004.

EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid. / Yeh, Dah Cherng; Chen, Dar Ren; Chao, Tsu Yi; Chen, Shin Cheh; Wang, Hwei Chung; Rau, Kun Ming; Feng, Yin Hsun; Chang, Yuan Ching; Lee, Kuan Der; Ou-Yang, Fu; Kuo, Wen Hung; Chang, King Jen; Lin, Yung Chang; Tseng, Ling Ming; Hou, Ming Feng.

In: In Vivo, Vol. 28, No. 5, 01.09.2014, p. 1001-1004.

Research output: Contribution to journalArticle

Yeh, DC, Chen, DR, Chao, TY, Chen, SC, Wang, HC, Rau, KM, Feng, YH, Chang, YC, Lee, KD, Ou-Yang, F, Kuo, WH, Chang, KJ, Lin, YC, Tseng, LM & Hou, MF 2014, 'EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid', In Vivo, vol. 28, no. 5, pp. 1001-1004.
Yeh, Dah Cherng ; Chen, Dar Ren ; Chao, Tsu Yi ; Chen, Shin Cheh ; Wang, Hwei Chung ; Rau, Kun Ming ; Feng, Yin Hsun ; Chang, Yuan Ching ; Lee, Kuan Der ; Ou-Yang, Fu ; Kuo, Wen Hung ; Chang, King Jen ; Lin, Yung Chang ; Tseng, Ling Ming ; Hou, Ming Feng. / EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid. In: In Vivo. 2014 ; Vol. 28, No. 5. pp. 1001-1004.
@article{f5aa6c7cbfb64a138c754e58002ac121,
title = "EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid",
abstract = "Background: We assessed the effect of zoledronic acid on quality of life (QOL) and pain outcome in breast cancer patients with bone metastases using the European Organization for Research and Treatment of Cancer bone metastases module (EORTC QLQ-BM22). Patients and Methods: Three hundred sixty-six breast cancer patients receiving zoledronic acid for bone metastases from 13 Centers were prospectively enrolled. QOL was evaluated using the EORTC QLQ-BM22 and pain outcome were measured monthly with a Visual Analog Scale (VAS) score for 24 months. Results: No significant change of functional scale (functional interference and psychosocial aspects) of the EORTC QLQ-BM22 was reported. Significant reduction of the symptom scale was noted after treatment compared with the baseline. The painful site subscale was significantly reduced during the first 12 months, with the exception the 6- month follow-up of point. Pain characteristics subscale was also significantly lower from the 2-month time point onwards. VAS scores indicated a significant reduction in pain over the course of the study to the 22-month time point follow-up compared to the baseline. Conclusion: Zoledronic acid treatment improved QOL of breast cancer patients with bone metastases by relieving bone pain.",
keywords = "Bone metastases, Breast cancer, Pain, Quality of life, Zoledronic acid",
author = "Yeh, {Dah Cherng} and Chen, {Dar Ren} and Chao, {Tsu Yi} and Chen, {Shin Cheh} and Wang, {Hwei Chung} and Rau, {Kun Ming} and Feng, {Yin Hsun} and Chang, {Yuan Ching} and Lee, {Kuan Der} and Fu Ou-Yang and Kuo, {Wen Hung} and Chang, {King Jen} and Lin, {Yung Chang} and Tseng, {Ling Ming} and Hou, {Ming Feng}",
year = "2014",
month = "9",
day = "1",
language = "English",
volume = "28",
pages = "1001--1004",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid

AU - Yeh, Dah Cherng

AU - Chen, Dar Ren

AU - Chao, Tsu Yi

AU - Chen, Shin Cheh

AU - Wang, Hwei Chung

AU - Rau, Kun Ming

AU - Feng, Yin Hsun

AU - Chang, Yuan Ching

AU - Lee, Kuan Der

AU - Ou-Yang, Fu

AU - Kuo, Wen Hung

AU - Chang, King Jen

AU - Lin, Yung Chang

AU - Tseng, Ling Ming

AU - Hou, Ming Feng

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Background: We assessed the effect of zoledronic acid on quality of life (QOL) and pain outcome in breast cancer patients with bone metastases using the European Organization for Research and Treatment of Cancer bone metastases module (EORTC QLQ-BM22). Patients and Methods: Three hundred sixty-six breast cancer patients receiving zoledronic acid for bone metastases from 13 Centers were prospectively enrolled. QOL was evaluated using the EORTC QLQ-BM22 and pain outcome were measured monthly with a Visual Analog Scale (VAS) score for 24 months. Results: No significant change of functional scale (functional interference and psychosocial aspects) of the EORTC QLQ-BM22 was reported. Significant reduction of the symptom scale was noted after treatment compared with the baseline. The painful site subscale was significantly reduced during the first 12 months, with the exception the 6- month follow-up of point. Pain characteristics subscale was also significantly lower from the 2-month time point onwards. VAS scores indicated a significant reduction in pain over the course of the study to the 22-month time point follow-up compared to the baseline. Conclusion: Zoledronic acid treatment improved QOL of breast cancer patients with bone metastases by relieving bone pain.

AB - Background: We assessed the effect of zoledronic acid on quality of life (QOL) and pain outcome in breast cancer patients with bone metastases using the European Organization for Research and Treatment of Cancer bone metastases module (EORTC QLQ-BM22). Patients and Methods: Three hundred sixty-six breast cancer patients receiving zoledronic acid for bone metastases from 13 Centers were prospectively enrolled. QOL was evaluated using the EORTC QLQ-BM22 and pain outcome were measured monthly with a Visual Analog Scale (VAS) score for 24 months. Results: No significant change of functional scale (functional interference and psychosocial aspects) of the EORTC QLQ-BM22 was reported. Significant reduction of the symptom scale was noted after treatment compared with the baseline. The painful site subscale was significantly reduced during the first 12 months, with the exception the 6- month follow-up of point. Pain characteristics subscale was also significantly lower from the 2-month time point onwards. VAS scores indicated a significant reduction in pain over the course of the study to the 22-month time point follow-up compared to the baseline. Conclusion: Zoledronic acid treatment improved QOL of breast cancer patients with bone metastases by relieving bone pain.

KW - Bone metastases

KW - Breast cancer

KW - Pain

KW - Quality of life

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84918572742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918572742&partnerID=8YFLogxK

M3 - Article

C2 - 25189922

AN - SCOPUS:84918572742

VL - 28

SP - 1001

EP - 1004

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 5

ER -